<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435759</url>
  </required_header>
  <id_info>
    <org_study_id>SPD489-209</org_study_id>
    <secondary_id>2011-003615-28</secondary_id>
    <nct_id>NCT01435759</nct_id>
  </id_info>
  <brief_title>SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder</brief_title>
  <official_title>A Phase 2, Multicenter, Double- Blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD)
      who are taking certain types of antidepressants but continue to have residual depression
      symptoms. The purpose of this study is to help answer the following questions:

        -  How safe is SPD489 for the supplemental treatment of depression and what are the side
           effects that might be related to it?

        -  Can SPD489 help patients with depression who are also taking an antidepressant?

        -  How much SPD489 should be given to patients with depression who are also taking an
           antidepressant?

        -  How does SPD489 compare to placebo in depressed patients who are also taking an
           antidepressant?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Montgomery-Çºsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)</measure>
    <time_frame>Augmentation Baseline (Week 8) to Week 16</time_frame>
    <description>MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. CHange in MADRS total score in Augmentsion Baseline to Week 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16</measure>
    <time_frame>From Augmentation Baseline (Week 8) to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16</measure>
    <time_frame>From Augmentation Baseline (Week 8) to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16</measure>
    <time_frame>From Augmentation Baseline (Week 8) to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1197</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Antidepressant + SPD489 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antidepressant + SPD489 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antidepressant + SPD489 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antidepressant + SPD489 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antidepressant + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg</intervention_name>
    <description>Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks</description>
    <arm_group_label>Antidepressant + SPD489 10 mg</arm_group_label>
    <other_name>Vyvanse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg</intervention_name>
    <description>Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks</description>
    <arm_group_label>Antidepressant + SPD489 30 mg</arm_group_label>
    <other_name>Vyvanse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg</intervention_name>
    <description>Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks</description>
    <arm_group_label>Antidepressant + SPD489 50 mg</arm_group_label>
    <other_name>Vyvanse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg</intervention_name>
    <description>Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks</description>
    <arm_group_label>Antidepressant + SPD489 70 mg</arm_group_label>
    <other_name>Vyvanse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant + Placebo</intervention_name>
    <description>oral, once daily for 8 weeks</description>
    <arm_group_label>Antidepressant + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Subject is able to provide written, personally signed and dated informed consent to
             participate in the study before completing any study-related procedures.

          2. Subject is between 18-65 years of age.

          3. Subject has a primary diagnosis of non-psychotic MDD.

          4. Subject has a MADRS total score 24

          5. Subject is willing and has an understanding and ability to fully comply with study
             procedures and restrictions defined in this protocol.

          6. Subject, who is female, must have a negative serum beta human chorionic gonadotropin
             (HCG) pregnancy test and a negative urine pregnancy test and agrees to comply with any
             applicable contraceptive requirements.

          7. Subject is able to swallow a capsule.

        Exclusion Criteria

          1. Subject whose current episode of MDD has not responded to an adequate treatment
             regimen.

          2. Subject who has a lifetime history of treatment resistant depression, defined as
             having not responded to adequate treatment with 2 or more treatment regimens.

          3. Subject has a current comorbid psychiatric disorder that is either controlled with
             medications prohibited in this study or is uncontrolled and associated with
             significant symptoms.

          4. Subject has been hospitalized (within the last 12 months) for their current MDD
             episode.

          5. Subject has a current or lifetime history of attention-deficit/hyperactivity disorder
             (ADHD).

          6. Subject has a first degree relative that has been diagnosed with bipolar I disorder.

          7. Subject has a recent history (within the last 6 months) of suspected substance abuse
             or dependence disorder.

          8. Subject is considered a suicide risk, has previously made a suicide attempt within the
             past 3 years, or is currently demonstrating active suicidal ideation.

          9. Subject has a concurrent chronic or acute illness or unstable medical condition.

         10. Subject has a history of seizures (other than infantile febrile seizures), any tic
             disorder, or a current diagnosis and/or a known family history of Tourette's Disorder,
             serious neurological disease, history of significant head trauma, dementia,
             cerebrovascular disease, Parkinson's disease, or intracranial lesions.

         11. Subject has known history of symptomatic cardiovascular disease, advanced
             arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm
             abnormalities, coronary artery disease, or other serious cardiac problems that may
             place them at increased vulnerability to the sympathomimetic effects of a stimulant
             medication.

         12. Subject has a history of thyroid disorder that has not been stabilized on thyroid
             medication or treatment within 3 months prior to the Screening Visit.

         13. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.

         14. Subject has glaucoma.

         15. Subject has any clinically significant ECG or clinical laboratory abnormalities at the
             Screening Visit.

         16. Subject has a history of moderate to severe hypertension.

         17. Current use of any other medication (including over-the-counter [OTC], herbal or
             homeopathic preparations) that has central nervous system effects.

         18. Subject has the potential to need to initiate or modify frequency of psychotherapy or
             to continue or initiate other treatments for depression, outside of those allowed in
             this protocol.

         19. Subject has had electroconvulsive therapy for the current depressive episode 3 months
             prior to the Lead-in Baseline Visit.

         20. The subject has a known or suspected intolerance or hypersensitivity to the
             investigational product.

         21. The subject has a known or suspected intolerance or hypersensitivity to any of the
             possible antidepressant treatments (escitalopram oxalate or venlafaxine HCL extended
             release.

         22. Subject has a positive urine drug result.

         23. Subject has a body mass index of &lt;18.5 or &gt;40.

         24. Subject is female and is pregnant or nursing.

         25. Subject has participated in another clinical study involving SPD489/NRP104 or has
             previously used commercial lisdexamfetamine dimesylate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhukar H Trivedi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical School, Dallas, Texas 75235</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Psychiatric Clinic Clinical Research Trials</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Coast Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanti Clinical Trials</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Innovation, Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Center for Clinical Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Clinical Trials</name>
      <address>
        <city>La Habra</city>
        <state>California</state>
        <zip>90631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Provate Practice of Andrew Leuchter, MD</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCSD - Feighner Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Orange County</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Affiliated Research Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Living</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Central Connecticut, Psychiatry &amp; Behavioral Health Research</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Clinical Research Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice - Amit Vijapura MD</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Neuroscience, Inc.</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fideltiy Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ali A. Kashfi, MD, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32839</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Central Florida</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kolin Research Group</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Behavioral Medicine, LLC</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Treatment Research Center, Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Center for Psychiatric Research</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Medicine Associates, LLC</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep and Behavior Medicine Institute</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Technology, Inc.</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedia Research, LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psyichatric Care and Research Center</name>
      <address>
        <city>O'Fallon</city>
        <state>Missouri</state>
        <zip>63368</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-America Clinical Research, LLC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Psychiatric Research Institute, LLC.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide LLC</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Neuroscience, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinlabs, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice - Daniel I. Rifkin MD PC</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, Inc.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Coast Clinical Trials, Inc.</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University, Dept. of Psychiatry</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology &amp; Neuroscience Center of Ohio</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Services</name>
      <address>
        <city>West Chester</city>
        <state>Pennsylvania</state>
        <zip>19380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Clinical Services</name>
      <address>
        <city>Friendswood</city>
        <state>Texas</state>
        <zip>77546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wharton Research Center, Inc.</name>
      <address>
        <city>Wharton</city>
        <state>Texas</state>
        <zip>77488</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grayline Clinical Drug Trials</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research Group</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean Foundation for Health, Research and Education, Inc.</name>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <zip>53562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Psychiatric Consultants, SC, dba, IPC Research</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Psicopatologia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BOA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cervino</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico de Medicina Familiar Mind Out Research</name>
      <address>
        <city>Caba</city>
        <zip>1417</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BA Psychiatric Research Center</name>
      <address>
        <city>Caba</city>
        <zip>C1012AAU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico SAMIC</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurotherapy Victoria</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Melbourne Clinic</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital, Mental Health Clinical Trials Unit</name>
      <address>
        <city>Elizabeth Vale</city>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred, Monash Alfred Psychiatry Research Centre</name>
      <address>
        <city>Victoria</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Health Mental Health Services</name>
      <address>
        <city>Victoria</city>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psocomed Estudios Medicos</name>
      <address>
        <city>Antofagasta</city>
        <state>il Region</state>
        <zip>1270244</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Especialidades Medicas L y S</name>
      <address>
        <city>Las Condes</city>
        <state>Santiago</state>
        <zip>7560356</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios y Tratemiento de Enfermedades Psiquiatricas</name>
      <address>
        <city>Las Condes</city>
        <state>Santiago</state>
        <zip>7580307</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedica Research Group</name>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Clinicos</name>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <zip>7510186</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Salud Mental y Psiquietriea Hospital y CRS El Pino</name>
      <address>
        <city>San Bernardo</city>
        <state>Santiago</state>
        <zip>8053095</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Barros Luco Trudsau</name>
      <address>
        <city>San Miguel</city>
        <state>Santiago</state>
        <zip>890085</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollins Park Hospital</name>
      <address>
        <city>Winwick</city>
        <state>Warrington Cheshire</state>
        <zip>WA2 8WA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radbourne Unit</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ADHD Mental Health Research Unit</name>
      <address>
        <city>Horsham</city>
        <zip>RH12 1RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University, Wolfson Research Centre</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rushcliffe Mental Health Team</name>
      <address>
        <city>Nottingham</city>
        <zip>NG2 7PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Chile</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>February 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 19, 2015</results_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antidepressant + Single-blind Placebo</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily single-blind placebo (matching SPD489).</description>
        </group>
        <group group_id="P2">
          <title>Antidepressant + Double-blind Placebo</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily double-blind placebo (matching SPD489).</description>
        </group>
        <group group_id="P3">
          <title>Antidepressant + Double-blind SPD489 10mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 10mg dose.</description>
        </group>
        <group group_id="P4">
          <title>Antidepressant + Double-blind SPD489 30mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 30mg dose.</description>
        </group>
        <group group_id="P5">
          <title>Antidepressant + Double-blind SPD489 50mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 50mg dose.</description>
        </group>
        <group group_id="P6">
          <title>Antidepressant + Double-blind SPD489 70mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 70mg dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Antidepressant Lead-in Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1197">Of these 1197 subjects, 19 subjects were not dosed.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="855"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="342"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met BP or Pulse Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="463">These subjects were not included in the Safety Dose Response Evaluable Set or Safety Analysis Set.</participants>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="78">One subject was not dosed.</participants>
                <participants group_id="P4" count="78">Two subjects were not dosed.</participants>
                <participants group_id="P5" count="78"/>
                <participants group_id="P6" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="397"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="69"/>
                <participants group_id="P6" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met BP or Pulse Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 post-augmentation baseline safety assessment (e.g. coming back for any visit, reporting of an adverse event [AE] or reporting the absence of AEs). Subjects who received only single-blind placebo were not included in this group.</population>
      <group_list>
        <group group_id="B1">
          <title>Antidepressant + Double-blind Placebo</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily double-blind placebo (matching SPD489).</description>
        </group>
        <group group_id="B2">
          <title>Antidepressant + Double-blind SPD489 10mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 10mg dose.</description>
        </group>
        <group group_id="B3">
          <title>Antidepressant + Double-blind SPD489 30mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 30mg dose.</description>
        </group>
        <group group_id="B4">
          <title>Antidepressant + Double-blind SPD489 50mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 50mg dose.</description>
        </group>
        <group group_id="B5">
          <title>Antidepressant + Double-blind SPD489 70mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 70mg dose.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="76"/>
            <count group_id="B4" value="78"/>
            <count group_id="B5" value="80"/>
            <count group_id="B6" value="389"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="10.48"/>
                    <measurement group_id="B2" value="39.1" spread="11.83"/>
                    <measurement group_id="B3" value="43.4" spread="12.06"/>
                    <measurement group_id="B4" value="43.8" spread="12.4"/>
                    <measurement group_id="B5" value="41.5" spread="10.81"/>
                    <measurement group_id="B6" value="42.3" spread="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>56-65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ARGENTINA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUSTRALIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHILE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED KINGDOM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="70"/>
                    <measurement group_id="B6" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16</title>
        <time_frame>From Augmentation Baseline (Week 8) to Week 16</time_frame>
        <population>Vital Signs Evaluable Set: All randomized subjects who had at least 1 valid vital signs measurement during the Dose Maintenance Period while on the target dose level of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant + Double-blind Placebo</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily double-blind placebo (matching SPD489).</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant + Double-blind SPD489 10mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 10mg dose.</description>
          </group>
          <group group_id="O3">
            <title>Antidepressant + Double-blind SPD489 30mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 30mg dose.</description>
          </group>
          <group group_id="O4">
            <title>Antidepressant + Double-blind SPD489 50mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 50mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Antidepressant + Double-blind SPD489 70mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 70mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16</title>
          <population>Vital Signs Evaluable Set: All randomized subjects who had at least 1 valid vital signs measurement during the Dose Maintenance Period while on the target dose level of investigational product.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="9.55"/>
                    <measurement group_id="O2" value="0.2" spread="8.58"/>
                    <measurement group_id="O3" value="0.5" spread="9.17"/>
                    <measurement group_id="O4" value="3.5" spread="7.82"/>
                    <measurement group_id="O5" value="2.6" spread="10.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The systolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>3.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.01</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 3.14, was based on MCP-Mod Analysis for the candidate model EMax.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The systolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>2.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.01</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 2.48, was based on MCP-Mod Analysis for the candidate model Exponential.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The systolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Mean</param_type>
            <param_value>3.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.01</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 3.26 was based on MCP-Mod Analysis for the candidate model Linear.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>MCP-Mod Analysis Method</method>
            <method_desc>The systolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>2.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.01</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 2.88, was based on MCP-Mod Analysis for the candidate model Logistic1.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The systolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>3.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.01</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 3.12, was based on MCP-Mod Analysis for the candidate model Logistic2.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16</title>
        <time_frame>From Augmentation Baseline (Week 8) to Week 16</time_frame>
        <population>Vital Signs Evaluable Set: All randomized subjects who had at least 1 valid vital signs measurement during the Dose Maintenance Period while on the target dose level of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant + Double-blind Placebo</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily double-blind placebo (matching SPD489).</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant + Double-blind SPD489 10mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 10mg dose.</description>
          </group>
          <group group_id="O3">
            <title>Antidepressant + Double-blind SPD489 30mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 30mg dose.</description>
          </group>
          <group group_id="O4">
            <title>Antidepressant + Double-blind SPD489 50mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 50mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Antidepressant + Double-blind SPD489 70mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 70mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16</title>
          <population>Vital Signs Evaluable Set: All randomized subjects who had at least 1 valid vital signs measurement during the Dose Maintenance Period while on the target dose level of investigational product.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="6.69"/>
                    <measurement group_id="O2" value="-0.9" spread="6.64"/>
                    <measurement group_id="O3" value="-0.1" spread="7.39"/>
                    <measurement group_id="O4" value="2.8" spread="6.58"/>
                    <measurement group_id="O5" value="1.9" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The diastolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>2.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 2.86 was based on MCP-Mod Analysis for the candidate model Emax.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The diastolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>1.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 2.59, was based on MCP-Mod Analysis for the candidate model Exponential.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Least Squares Means</method>
            <method_desc>The diastolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>MCP-Mod Analysis</param_type>
            <param_value>2.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 3.28, was based on MCP-Mod Analysis for the candidate model Linear.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The diastolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>2.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 2.93, was based on MCP-Mod Analysis for the candidate model Logistic1.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The diastolic blood pressure p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>2.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 3.13, was based on MCP-Mod Analysis for the candidate model Logistic2.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16</title>
        <time_frame>From Augmentation Baseline (Week 8) to Week 16</time_frame>
        <population>Vital Signs Evaluable Set: All randomized subjects who had at least 1 valid vital signs measurement during the Dose Maintenance Period while on the target dose level of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant + Double-blind Placebo</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily double-blind placebo (matching SPD489).</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant + Double-blind SPD489 10mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 10mg dose.</description>
          </group>
          <group group_id="O3">
            <title>Antidepressant + Double-blind SPD489 30mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 30mg dose.</description>
          </group>
          <group group_id="O4">
            <title>Antidepressant + Double-blind SPD489 50mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 50mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Antidepressant + Double-blind SPD489 70mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 70mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16</title>
          <population>Vital Signs Evaluable Set: All randomized subjects who had at least 1 valid vital signs measurement during the Dose Maintenance Period while on the target dose level of investigational product.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="9.95"/>
                    <measurement group_id="O2" value="0.8" spread="7.32"/>
                    <measurement group_id="O3" value="5.3" spread="8.08"/>
                    <measurement group_id="O4" value="4.0" spread="9.80"/>
                    <measurement group_id="O5" value="6.0" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The pulse p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>4.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 4.24, was based on MCP-Mod Analysis for the candidate model Emax</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The pulse p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>3.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 3.36, was based on MCP-Mod Analysis for the candidate model Expontential.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The pulse p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>4.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 4.10, was based on MCP-Mod Analysis for the candidate model Linear.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The pulse p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>4.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 4.39, was based on MCP-Mod Analysis for the candidate model Logistic1.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MCP-Mod Analysis</method>
            <method_desc>The pulse p-value was based on a critical value of 1.99 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>4.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 4.39 was based on MCP-Mod Analysis for the candidate model Logistic2.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Montgomery-Çºsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)</title>
        <description>MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. CHange in MADRS total score in Augmentsion Baseline to Week 16.</description>
        <time_frame>Augmentation Baseline (Week 8) to Week 16</time_frame>
        <population>Dose Response Evaluable Set (DRES): All randomized subjects who had at least 1 valid primary efficacy measurement (MADRS total score) during the Dose Maintenance Period (Weeks 11-16) while on the target dose level of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant + Double-blind Placebo</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily double-blind placebo (matching SPD489).</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant + Double-blind SPD489 10mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 10mg dose.</description>
          </group>
          <group group_id="O3">
            <title>Antidepressant + Double-blind SPD489 30mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 30mg dose.</description>
          </group>
          <group group_id="O4">
            <title>Antidepressant + Double-blind SPD489 50mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 50mg dose.</description>
          </group>
          <group group_id="O5">
            <title>Antidepressant + Double-blind SPD489 70mg</title>
            <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 70mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Montgomery-Çºsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)</title>
          <description>MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. CHange in MADRS total score in Augmentsion Baseline to Week 16.</description>
          <population>Dose Response Evaluable Set (DRES): All randomized subjects who had at least 1 valid primary efficacy measurement (MADRS total score) during the Dose Maintenance Period (Weeks 11-16) while on the target dose level of investigational product.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" lower_limit="-7.2" upper_limit="-3.5"/>
                    <measurement group_id="O2" value="-6.7" lower_limit="-8.6" upper_limit="-4.9"/>
                    <measurement group_id="O3" value="-5.3" lower_limit="-7.1" upper_limit="-3.4"/>
                    <measurement group_id="O4" value="-6.1" lower_limit="-8.1" upper_limit="-4.1"/>
                    <measurement group_id="O5" value="-6.3" lower_limit="-8.2" upper_limit="-4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis of Dose-Response Using the MCP-Mod Analysis Method</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>Any p-value &lt;=0.10 indicates successful establishment of dose-response relationship.</p_value_desc>
            <method>MCP-Mod Analysis Method</method>
            <method_desc>The adjusted p-value was based on a critical value of 2.02 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>-.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.07</dispersion_value>
            <ci_n_sides>1-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 0.10, was based on MCP-Mod Analysis from the linear contrast using optimal coefficients for the pre-specified candidate model Betamod.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis of Dose-Response Using the MCP-Mod Analysis Method.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.942</p_value>
            <p_value_desc>Any p-value &lt;=0.10 indicates successful establishment of dose-response relationship.</p_value_desc>
            <method>MCP-Mod Analysis</method>
            <method_desc>The adjusted p-value was based on a critical value of 2.02 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.06</dispersion_value>
            <ci_n_sides>1-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 0.41, was based on MCP-Mod Analysis from the linear contrast using optimal coefficients for the pre-specified candidate model Emax.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis of Dose-Response Using the MCP-Mod Analysis Method.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.995</p_value>
            <p_value_desc>Any p-value &lt;=0.10 indicates successful establishment of dose-response relationship.</p_value_desc>
            <method>MCP-Mod Analysis</method>
            <method_desc>The adjusted p-value was based on a critical value of 2.02 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.06</dispersion_value>
            <ci_n_sides>1-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 0.20, was based on MCP-Mod Analysis from the linear contrast using optimal coefficients for the pre-specified candidate model Linear.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis of Dose-Response Using the MCP-Mod Analysis Method</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>Any p-value &lt;=0.10 indicates successful establishment of dose-response relationship.</p_value_desc>
            <method>MCP-Mod Analysis</method>
            <method_desc>The adjusted p-value was based on a critical value of 2.02 from a multivariate-t distribution with 341 degrees of freedom.</method_desc>
            <param_type>Least Squares Means</param_type>
            <param_value>-.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.07</dispersion_value>
            <ci_n_sides>1-Sided</ci_n_sides>
            <estimate_desc>The t-statistic used for this analysis, 0.30, was based on MCP-Mod Analysis from the linear contrast using optimal coefficients for the pre-specified candidate model Logistic.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 post-augmentation baseline safety assessment (e.g. coming back for any visit, reporting of an AE or reporting the absence of AEs). Subjects who received only single-blind placebo were not included in this group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Antidepressant + Double-blind Placebo</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily double-blind placebo (matching SPD489).</description>
        </group>
        <group group_id="E2">
          <title>Antidepressant + Double-blind SPD489 10mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 10mg dose.</description>
        </group>
        <group group_id="E3">
          <title>Antidepressant + Double-blind SPD489 30mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 30mg dose.</description>
        </group>
        <group group_id="E4">
          <title>Antidepressant + Double-blind SPD489 50mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 50mg dose.</description>
        </group>
        <group group_id="E5">
          <title>Antidepressant + Double-blind SPD489 70mg</title>
          <description>Subjects received unblinded standard antidepressant therapy (either escitalopram oxalate or venlafaxine hydrochloride extended-release titrated to the maximum tolerated dose) plus oral, once daily over-encapsulated SPD489 as a 70mg dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="78"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

